TENAX THERAPEUTICS, INC. Revenues
TENAX THERAPEUTICS, INC. (TENX) reported Revenues of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-16.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2017-03-16
- TENAX THERAPEUTICS, INC. revenues for the quarter ending 2015-04-30 was $49.29K.
- TENAX THERAPEUTICS, INC. revenues for the quarter ending 2015-01-31 was $0.00, a 100.00% decline year-over-year.
- TENAX THERAPEUTICS, INC. revenues for the quarter ending 2014-10-31 was $0.00, a 100.00% decline year-over-year.
- TENAX THERAPEUTICS, INC. revenues for the quarter ending 2014-07-31 was $0.00, a 100.00% decline year-over-year.
- TENAX THERAPEUTICS, INC. revenues for fiscal 2016 was $0.00.
- TENAX THERAPEUTICS, INC. revenues for fiscal 2015 was $49.29K, a 68.99% decline from fiscal 2014.
- TENAX THERAPEUTICS, INC. revenues for fiscal 2014 was $158.93K, a 86.66% decline from fiscal 2013.
- TENAX THERAPEUTICS, INC. revenues for fiscal 2013 was $1.19M, a 227.37% increase from fiscal 2012.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 8 month | Revenues 9 month | Revenues 12 month | Revenues 533 month | Revenues 536 month | Revenues 539 month | Revenues 542 month | Revenues 545 month | Revenues 554 month | Revenues 557 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-16 | |||||||||||
| 2015-12-31 | $0.00 10-K · filed 2017-03-16 | |||||||||||
| 2015-04-30 | $49.29K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $49.29K derived: sum of 2 quarters · filed 2017-03-16 | $49.29K derived: sum of 3 quarters · filed 2017-03-16 | $49.29K 10-K · filed 2017-03-16 | ||||||||
| 2015-01-31 | $0.00 10-Q · filed 2015-03-17 | $0.00 derived: sum of 2 quarters · filed 2015-03-17 | $0.00 10-Q · filed 2015-03-17 | -$104.45K derived: sum of 4 quarters · filed 2017-03-16 | ||||||||
| 2014-10-31 | $0.00 10-Q · filed 2014-12-15 | $0.00 10-Q · filed 2014-12-15 | -$104.45K derived: sum of 3 quarters · filed 2017-03-16 | -$62.59K derived: sum of 4 quarters · filed 2017-03-16 | ||||||||
| 2014-07-31 | $0.00 10-Q · filed 2014-09-15 | -$104.45K derived: sum of 2 quarters · filed 2017-03-16 | -$62.59K derived: sum of 3 quarters · filed 2017-03-16 | -$6.88K derived: sum of 4 quarters · filed 2017-03-16 | ||||||||
| 2014-04-30 | -$104.45K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$62.59K derived: sum of 2 quarters · filed 2017-03-16 | -$6.88K derived: sum of 3 quarters · filed 2017-03-16 | $158.93K 10-K · filed 2017-03-16 | ||||||||
| 2014-01-31 | $41.86K 10-Q · filed 2015-03-17 | $97.57K derived: sum of 2 quarters · filed 2015-03-17 | $263.38K 10-Q · filed 2015-03-17 | $444.95K derived: sum of 4 quarters · filed 2016-03-14 | $1.93M 10-Q · filed 2014-03-17 | |||||||
| 2013-10-31 | $55.71K 10-Q · filed 2014-12-15 | $221.51K 10-Q · filed 2014-12-15 | $403.08K derived: sum of 3 quarters · filed 2016-03-14 | $625.47K derived: sum of 4 quarters · filed 2016-03-14 | $1.89M 10-Q · filed 2013-12-17 | |||||||
| 2013-07-31 | $165.80K 10-Q · filed 2014-09-15 | $347.38K derived: sum of 2 quarters · filed 2016-03-14 | $569.76K derived: sum of 3 quarters · filed 2016-03-14 | $1.08M derived: sum of 4 quarters · filed 2016-03-14 | $1.83M 10-Q · filed 2013-09-17 | |||||||
| 2013-04-30 | $181.57K derived: 10-KT 12 month − 10-Q 9 month · filed 2016-03-14 | $403.96K derived: sum of 2 quarters · filed 2016-03-14 | $918.83K derived: sum of 3 quarters · filed 2016-03-14 | $1.19M 10-KT · filed 2016-03-14 | $1.67M 10-K · filed 2013-06-26 | |||||||
| 2013-01-31 | $222.39K 10-Q · filed 2014-03-17 | $737.26K derived: sum of 2 quarters · filed 2014-03-17 | $1.01M 10-Q · filed 2014-03-17 | $1.10M derived: sum of 4 quarters · filed 2014-03-17 | $1.48M 10-Q · filed 2013-03-18 | |||||||
| 2012-10-31 | $514.87K 10-Q · filed 2013-12-17 | $786.97K 10-Q · filed 2013-12-17 | $882.46K derived: sum of 3 quarters · filed 2013-12-17 | $1.03M derived: sum of 4 quarters · filed 2013-12-17 | $1.26M 10-Q · filed 2012-12-14 | |||||||
| 2012-07-31 | $272.10K 10-Q · filed 2013-09-17 | $367.58K derived: sum of 2 quarters · filed 2013-09-17 | $515.85K derived: sum of 3 quarters · filed 2013-09-17 | $611.00K derived: sum of 4 quarters · filed 2013-09-17 | $747.40K 10-Q · filed 2012-09-19 | |||||||
| 2012-04-30 | $95.49K derived: 10-K 12 month − 10-Q 9 month · filed 2013-06-26 | $243.75K derived: sum of 2 quarters · filed 2013-06-26 | $338.91K derived: sum of 3 quarters · filed 2013-06-26 | $363.78K 10-K · filed 2013-06-26 | $475.30K 10-K · filed 2012-07-25 | |||||||
| 2012-01-31 | $148.26K 10-Q · filed 2013-03-18 | $243.42K derived: sum of 2 quarters · filed 2013-03-18 | $268.29K 10-Q · filed 2013-03-18 | $312.64K derived: sum of 4 quarters · filed 2013-03-18 | $379.81K 10-Q · filed 2012-03-15 | |||||||
| 2011-10-31 | $95.16K 10-Q · filed 2012-12-14 | $120.03K 10-Q · filed 2012-12-14 | $164.37K derived: sum of 3 quarters · filed 2012-12-14 | $190.96K derived: sum of 4 quarters · filed 2012-12-14 | $231.55K 10-Q · filed 2011-12-15 | |||||||
| 2011-07-31 | $24.87K 10-Q · filed 2012-09-19 | $69.22K derived: sum of 2 quarters · filed 2012-09-19 | $95.80K derived: sum of 3 quarters · filed 2012-09-19 | $122.93K derived: sum of 4 quarters · filed 2012-09-19 | ||||||||
| 2011-04-30 | $44.34K derived: 10-K 12 month − 10-Q 9 month · filed 2012-07-25 | $70.93K derived: sum of 2 quarters · filed 2012-07-25 | $98.06K derived: sum of 3 quarters · filed 2012-07-25 | $103.17K 10-K · filed 2012-07-25 | ||||||||
| 2011-01-31 | $26.59K 10-Q · filed 2012-03-15 | $53.72K derived: sum of 2 quarters · filed 2012-03-15 | $58.83K 10-Q · filed 2012-03-15 | |||||||||
| 2010-10-31 | $27.13K 10-Q · filed 2011-12-15 | $32.24K 10-Q · filed 2011-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |